EMA To Begin ‘Rolling Review’ of Gilead’s Remdesivir for COVID-19

The EMA’s Committee for Medicinal Products for Human Use (CHMP) has begun a “rolling review” of Gilead’s remdesivir for COVID-19 aimed at cutting its review time from months to weeks.

The CHMP will appoint leaders to review the drug while it is still under development. The EMA normally requires trial data to be available at the start of an evaluation.

The agency noted the positive results from a National Institutes of Health clinical trial of the antiviral drug, but said it is too early to draw any conclusions.